Humanized antibodies that recognize beta amyloid peptide

• US 7,189,819 B2
• Filed: 12/06/2001
• Issued: 03/13/2007
• Est. Priority Date: 12/06/2000
• Status: Expired due to Term

• Current Assignee: Janssen Alzheimer Immunotherapy (Johnson & Johnson), Volkswagen AG
• Original Assignee: Neuralab Ltd. (Perrigo Company PLC), Wyeth (Pfizer Inc.)
• Inventors: Saldanha, Jose William, Basi, Guriq
• Primary Examiner(s): Andres; Janet L.
• Assistant Examiner(s): BALLARD, KIMBERLY
• Application Number:
  US10/010,942
• Publication Number:
  US 20030165496A1
• Time in Patent Office: 1,923 Days
• Field of Search: 530/387.1, 530/387.2, 530/387.3, 530/387.9, 530/388.1, 530/388.15
• US Class Current: 530/387.3
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 2039/53 DNA (RNA) vaccination
• CPC Class Codes: A61K 2039/55505 Inorganic adjuvants
• CPC Class Codes: A61K 2039/55566 Emulsions, e.g. Freund's adjuvant, MF59
• CPC Class Codes: A61K 2039/55572 Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
• CPC Class Codes: A61K 2039/55577 Saponins; Quil A; QS21; ISCOMS
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 38/1709 from mammals
• CPC Class Codes: A61K 38/193 Colony stimulating factors [CSF]
• CPC Class Codes: A61K 39/00 Medicinal preparations containing antigens or antibodies materials for immunoassay G01N33/53
• CPC Class Codes: A61K 39/0007 Nervous system antigens; Prions
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/14 for treating abnormal movements, e.g. chorea, dyskinesia
• CPC Class Codes: A61P 25/16 Anti-Parkinson drugs
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07K 14/4711 Alzheimer's disease; Amyloid plaque core protein
• CPC Class Codes: C07K 16/18 against material from animals or humans
• CPC Class Codes: C07K 2317/24 containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
• CPC Class Codes: C07K 2317/567 : Framework region [FR]
• CPC Class Codes: C07K 2317/77 : Internalization into the cell
• CPC Class Codes: C07K 2319/00 : Fusion polypeptide

Abstract

The invention provides improves agents and methods for treatment of diseases associated with amyloid deposits of Aβ in the brain of a patient. Preferred agents include humanized antibodies.

Claims

1. A humanized immunoglobulin which specifically binds beta amyloid peptide (Aβ

), or antigen binding fragment thereof, the humanized immunoglobulin or antigen binding fragment comprising a light chain comprising

(i) the variable region complementarity determining regions (CDRs) from the 3D6 immunoglobulin light chain variable region sequence set forth as SEQ ID NO;

2, and

(ii) a variable framework region from a human acceptor immunoglobulin light chain, provided that at least three framework residues selected from the group consisting of L1, L2, L36 and L46 (Kabat numbering convention) are substituted with the corresponding amino acid residues from the mouse 3D6 light chain variable region sequence.

2. The humanized immunoglobulin or antigen binding fragment of claim 1, wherein the human acceptor light chain is of the subtype kappa II (Kabat convention).

3. The humanized immunoglobulin or antigen binding fragment of claim 2, wherein the human acceptor light chain is selected from the group consisting of Kabat ID 019230, Kabat ID 005131, Kabat ID 005058, Kabat ID 005057, Kabat ID 005059, Kabat ID U21040 and Kabat ID U41645.

4. The humanized immunoglobulin or antigen binding fragment of claim 3, wherein the human acceptor light chain is Kabat ID 019230.

5. The humanized immunoglobulin or antigen binding fragment of claim 1, wherein the light chain variable region comprises at least one rare human framework residue and wherein the rare human framework residue is substituted with an amino acid residue which is common for human variable light chain sequences at that position.

6. The humanized immunoglobulin or antigen binding fragment of claim 5, wherein the rare framework residue is selected based on occurrence at that position in less than 10% of human light chain variable region sequences in the light chain variable region subgroup, and the common residue is selected based on an occurrence at that position in greater than 50% of sequences in the light chain variable region subgroup.

7. The humanized immunoglobulin or antigen binding fragment of claim 1, wherein the light chain variable region comprises at least one rare human framework residue and wherein the rare human framework residue is substituted with a corresponding amino acid residue from a germline variable light chain sequence.

8. The humanized immunoglobulin or antigen binding fragment of claim 7, wherein the germline variable light chain sequence is selected from the group consisting of A1, A17, A18, A2, and A19.

9. A pharmaceutical composition comprising the humanized immunoglobulin or antigen binding fragment of claim 1 and a pharmaceutical carrier.

10. A humanized immunoglobulin which specifically binds amyloid beta peptide (Aβ

), or antigen binding fragment thereof, the humanized immunoglobulin or antigen binding fragment comprising a heavy chain comprising

(i) the variable region complementarity determining regions (CDRs) from the 3D6 heavy chain variable region sequence set forth as SEQ ID NO;

4, and

(ii) a variable framework region from a human acceptor immunoglobulin heavy chain, provided that at least the framework residues H49, H93 and H94 (Kabat numbering convention) are substituted with the corresponding amino acid residues from the mouse 3D6 heavy chain variable region sequence.

11. The humanized immunoglobulin or antigen binding fragment of claim 10, wherein the human acceptor heavy chain is of the subtype III (Kabat convention).

12. The humanized immunoglobulin or antigen binding fragment of claim 11, wherein the human acceptor heavy chain is selected from the group consisting of Kabat ID 045919, Kabat ID 000459, Kabat ID 000553, Kabat ID 000386 and Kabat ID M23691.

13. The humanized immunoglobulin or antigen binding fragment of claim 12, wherein the human acceptor heavy chain is Kabat ID 045919.

14. The humanized immunoglobulin or antigen binding fragment of claim 10, wherein the heavy chain variable region comprises at least one rare human framework residue and wherein the rare human framework residue is substituted with an amino acid residue which is common for human variable heavy chain sequences at that position.

15. The humanized immunoglobulin or antigen binding fragment of claim 14, wherein the rare framework residue is selected based on occurrence at that position in less than 10% of human heavy chain variable region sequences in the heavy chain variable region subgroup, and the common residue is selected based on an occurrence at that position in greater than 50% of sequences in the heavy chain variable region subgroup.

16. The humanized immunoglobulin or antigen binding fragment of claim 10, wherein the heavy chain variable region comprises at least one rare human framework residue and wherein the rare human framework residue is substituted with a corresponding amino acid residue from a germline variable heavy chain sequence.

17. The humanized immunoglobulin or antigen binding fragment of claim 16, wherein the germline variable heavy chain sequence is selected from the group consisting of VH3-48, VH3-23, VH3-7, VH3-21 and VH3-11.

18. The humanized immunoglobulin or antigen binding fragment of claim 17, wherein the germline variable heavy chain sequence is VH3-23.

19. A pharmaceutical composition comprising the humanized immunoglobulin or antigen binding fragment of claim 10 and a pharmaceutical carrier.

20. A humanized immunoglobulin which specifically binds beta amyloid peptide (Aβ

), or antigen binding fragment thereof, the humanized immunoglobulin or antigen binding fragment comprising a light chain comprising the complementarity determining regions (CDRs) and variable region framework residues L1, L2, L36 and L46 (Kabat numbering convention) from the monoclonal antibody 3D6 light chain, wherein the remainder of the light chain is from a human immunoglobulin.

21. The humanized immunoglobulin or antigen binding fragment of claim 20, wherein the human acceptor light chain is of the subtype kappa II (Kabat convention).

22. The humanized immunoglobulin or antigen binding fragment of claim 21, wherein the human acceptor light chain is selected from the group consisting of Kabat ID 019230, Kabat ID 005131, Kabat ID 005058, Kabat ID 005057, Kabat ID 005059, Kabat ID U21040 and Kabat ID U41645.

23. The humanized immunoglobulin or antigen binding fragment of claim 22, wherein the human acceptor light chain is Kabat ID 019230.

24. The humanized immunoglobulin or antigen binding fragment of claim 20, wherein the light chain variable region comprises at least one rare human framework residue and wherein the rare human framework residue is substituted with an amino acid residue which is common for human variable light chain sequences at that position.

25. The humanized immunoglobulin or antigen binding fragment of claim 24, wherein the rare framework residue is selected based on occurrence at that position in less than 10% of human light chain variable region sequences in the light chain variable region subgroup, and the common residue is selected based on an occurrence at that position in greater than 50% of sequences in the light chain variable region subgroup.

26. A pharmaceutical composition comprising the humanized immunoglobulin or antigen binding fragment of claim 24 and a pharmaceutical carrier.

27. The humanized immunoglobulin or antigen binding fragment of claim 20, wherein the light chain variable region comprises at least one rare human framework residue and wherein the rare human framework residue is substituted with a corresponding amino acid residue from a germline variable light chain sequence.

28. The humanized immunoglobulin or antigen binding fragment of claim 27, wherein the germline variable light chain sequence is selected from the group consisting of A1, A17, A18, A2, and A19.

29. A pharmaceutical composition comprising the humanized immunoglobulin or antigen binding fragment of claim 27 and a pharmaceutical carrier.

30. A pharmaceutical composition comprising the humanized immunoglobulin or antigen binding fragment of claim 20 and a pharmaceutical carrier.

31. A humanized immunoglobulin which specifically binds beta amyloid peptide (Aβ

), or antigen binding fragment thereof, the humanized immunoglobulin or antigen binding fragment comprising a heavy chain comprising the complementarity determining regions (CDRs) and variable region framework residues H49, H93 and H94 (Kabat numbering convention) from the monoclonal antibody 3D6 heavy chain, wherein the remainder of the heavy chain is from a human immunoglobulin.

32. The humanized immunoglobulin or antigen binding fragment of claim 31, wherein the human acceptor heavy chain is of the subtype III (Kabat convention).

33. The humanized immunoglobulin or antigen binding fragment of claim 32, wherein the human acceptor heavy chain is selected from the group consisting of Kabat ID 045919, Kabat ID 000459, Kabat ID 000553, Kabat ID 000386 and Kabat ID M23691.

34. The humanized immunoglobulin or antigen binding fragment of claim 33, wherein the human acceptor heavy chain is Kabat ID 045919.

35. The humanized immunoglobulin or antigen binding fragment of claim 31, wherein the heavy chain variable region comprises at least one rare human framework residue and wherein the rare human framework residue is substituted with a corresponding amino acid residue from a germline variable heavy chain sequence.

36. The humanized immunoglobulin or antigen binding fragment of claim 35, wherein the germline variable heavy chain sequence is selected from the group consisting of VH3-48, VH3-23, VH3-7, VH3-21 and VH3-11.

37. The humanized immunoglobulin or antigen binding fragment of claim 36, wherein the germline variable heavy chain sequence is VH3-23.

38. A pharmaceutical composition comprising the humanized immunoglobulin or antigen binding fragment of claim 35 and a pharmaceutical carrier.

39. The humanized immunoglobulin or antigen binding fragment of claim 31, wherein the heavy chain variable region comprises at least one rare human framework residue and wherein the rare human framework residue is substituted with an amino acid residue which is common for human variable heavy chain sequences at that position.

40. The humanized immunoglobulin or antigen binding fragment of claim 39, wherein the rare framework residue is selected based on occurrence at that position in less than 10% of human heavy chain variable region sequences in the heavy chain variable region subgroup, and the common residue is selected based on an occurrence at that position in greater than 50% of sequences in the heavy chain variable region subgroup.

41. A pharmaceutical composition comprising the humanized immunoglobulin or antigen binding fragment of claim 39 and a pharmaceutical carrier.

42. A pharmaceutical composition comprising the humanized immunoglobulin or antigen binding fragment of claim 31 and a pharmaceutical carrier.

43. A humanized immunoglobulin which specifically binds beta amyloid peptide, or antigen binding fragment thereof, the humanized immunoglobulin or antigen binding fragment comprising a light chain selected from the group consisting of:

(a) a light chain comprising the variable region complementarity determining regions (CDRs) from the 3D6 immunoglobulin light chain variable region sequence set forth as SEQ ID NO;

2, and a variable framework region from a human acceptor immunoglobulin light chain, provided that at least three framework residues selected from the group consisting of L1, L2, L36 and L46 (Kabat numbering convention) are substituted with the corresponding amino acid residues from the mouse 3D6 light chain variable region sequence;

(b) a light chain comprising the complementarity determining regions (CDRs) and variable region framework residues L1, L2, L36 and L46 (Kabat numbering convention) from the monoclonal antibody 3D6 light chain, wherein the remainder of the light chain is from a human immunoglobulin; and

(c) a light chain comprising the complementarity determining regions (CDRs) and variable region framework residues L2, L36 and L46 (Kabat numbering convention) from the monoclonal antibody 3D6 light chain, wherein the remainder of the light chain is from a human immunoglobulin,

and a heavy chain selected from the group consisting of;

(a) a heavy chain comprising the variable region complementarity determining regions (CDRs) from the 3D6 heavy chain variable region sequence set forth as SEQ ID NO;

4, and a variable framework region from a human acceptor immunoglobulin heavy chain, provided that at least the framework residues H49, H93 and H94 (Kabat numbering convention) are substituted with the corresponding amino acid residues from the mouse 3D6 heavy chain variable region sequence; and

(b) a heavy chain comprising the complementarity determining regions (CDRs) and variable framework residues H49, H93 and H94 (Kabat numbering convention) from the monoclonal antibody 3D6 heavy chain, wherein the remainder of the heavy chain is from a human immunoglobulin.

44. The humanized immunoglobulin or antigen binding fragment of claim 43, which specifically binds to beta amyloid peptide (Aβ

) with a binding affinity of at least 10⁷ M<sup>−

1</sup>.

45. The humanized immunoglobulin or antigen binding fragment of claim 43, which specifically binds to beta amyloid peptide (Aβ

) with a binding affinity of at least 10⁸ M<sup>−

1</sup>.

46. The humanized immunoglobulin or antigen binding fragment of claim 43, which specifically binds to beta amyloid peptide (Aβ

) with a binding affinity of at least 10⁹ M<sup>−

1</sup>.

47. The humanized immunoglobulin or antigen binding fragment of claim 43, wherein the heavy chain isotype is γ

1.

48. A pharmaceutical composition comprising the humanized immunoglobulin or antigen binding fragment of claim 47 and a pharmaceutical carrier.

49. The humanized immunoglobulin or antigen binding fragment of claim 43, which binds to both soluble beta amyloid peptide (Aβ

) and aggregated Aβ

.

50. The humanized immunoglobulin or antigen binding fragment of claim 49, wherein the soluble beta amyloid peptide (Aβ

) is disaggregated Aβ

.

51. The humanized immunoglobulin or antigen binding fragment of claim 43, which mediates phagocytosis of beta amyloid peptide (Aβ

).

52. The humanized immunoglobulin or antigen binding fragment of claim 43, which crosses the blood-brain barrier in a subject.

53. The humanized immunoglobulin or antigen binding fragment of claim 43, which reduces both beta amyloid peptide (Aβ

) burden and neuritic dystrophy in a subject.

54. A pharmaceutical composition comprising the humanized immunoglobulin or antigen binding fragment of claim 43 and a pharmaceutical carrier.

55. A humanized immunoglobulin which specifically binds to beta amyloid peptide (Aβ

), or antigen binding fragment thereof, the humanized immunoglobulin or antigen binding fragment comprising a light chain comprising the complementarity determining regions (CDRs) and variable region framework residues L2, L36 and L46 (Kabat numbering convention) from the monoclonal antibody 3D6 light chain, wherein the remainder of the light chain is from a human immunoglobulin.

56. A pharmaceutical composition comprising the humanized immunoglobulin or antigen binding fragment of claim 55 and a pharmaceutical carrier.

57. The humanized immunoglobulin or antigen binding fragment of claim 55, wherein the human acceptor light chain is of the subtype kappa II (Kabat convention).

58. The humanized immunoglobulin or antigen binding fragment of claim 57, wherein the human acceptor light chain is selected from the group consisting of Kabat ID 019230, Kabat ID 005131, Kabat ID 005058, Kabat 005057, Kabat ID 005059, Kabat ID U21040 and Kabat ID U41645.

59. The humanized immunoglobulin or antigen binding fragment of claim 58, wherein the human acceptor light chain is Kabat ID 019230.

60. The humanized immunoglobulin or antigen binding fragment of claim 55, wherein the light chain variable region comprises at least one rare human framework residue and wherein the rare human framework residue is substituted with an amino acid residue which is common for human variable light chain sequences at that position.

61. The humanized immunoglobulin or antigen binding fragment of claim 60, wherein the rare framework residue is selected based on occurrence at that position in less than 10% of human light chain variable region sequences in the light chain variable region subgroup, and the common residue is selected based on an occurrence at that position in greater than 50% of sequences in the light chain variable region subgroup.

62. The humanized immunoglobulin or antigen binding fragment of claim 55, wherein the light chain variable region comprises at least one rare human framework residue and wherein the rare human framework residue is substituted with a corresponding amino acid residue from a germline variable light chain sequence.

63. The humanized immunoglobulin or antigen binding fragment of claim 62, wherein the germline variable light chain sequence is selected from the group consisting of A1, A17, A18, A2, and A19.